Disc Medicine (NASDAQ:IRON) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Disc Medicine (NASDAQ:IRON) from a hold rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other analysts have also recently weighed in on the company. Wells Fargo & Company lifted their price objective on Disc Medicine from $79.00 to $86.00 and gave the company an “overweight” rating in a research report on Wednesday, September 16th. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Disc Medicine in a research report on Thursday, September 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Disc Medicine in a research note on Tuesday, September 1st. Jefferies Financial Group restated a “buy” rating and issued a $128.00 target price on shares of Disc Medicine in a research note on Thursday, September 10th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Disc Medicine in a research report on Thursday, September 10th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $115.60.

Disc Medicine Trading Up 38.9%

Shares of IRON opened at $78.93 on Friday. Disc Medicine has a 1-year low of $40.00 and a 1-year high of $99.50. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The firm’s 50-day moving average price is $71.56 and its 200-day moving average price is $71.29. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of -12.00 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. Sell-side analysts anticipate that Disc Medicine will post -6.61 EPS for the current year.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, COO Jonathan Yu sold 8,796 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rahul Khara sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the insider directly owned 52,324 shares of the company’s stock, valued at $4,185,920. This represents a 8.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 131,221 shares of company stock worth $10,239,760 in the last ninety days. 3.76% of the stock is owned by company insiders.

Institutional Trading of Disc Medicine

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. boosted its holdings in Disc Medicine by 191.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after acquiring an additional 735,300 shares in the last quarter. Opaleye Management Inc. grew its stake in shares of Disc Medicine by 103.1% in the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after acquiring an additional 434,000 shares during the last quarter. Engineers Gate Manager LP increased its holdings in shares of Disc Medicine by 110.9% during the second quarter. Engineers Gate Manager LP now owns 19,552 shares of the company’s stock valued at $1,430,000 after acquiring an additional 10,282 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of Disc Medicine by 139.3% during the second quarter. Squarepoint Ops LLC now owns 75,872 shares of the company’s stock valued at $5,549,000 after acquiring an additional 44,163 shares in the last quarter. Finally, Arizona State Retirement System raised its position in shares of Disc Medicine by 2.4% in the 2nd quarter. Arizona State Retirement System now owns 6,844 shares of the company’s stock worth $501,000 after purchasing an additional 160 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Key Stories Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: The successful Phase 3 results significantly improve the outlook for bitopertin, which Disc Medicine plans to resubmit for FDA approval by the end of 2026. The drug could become a disease-modifying treatment for EPP, addressing a substantial unmet medical need. Disc Medicine’s rare disease drug succeeds in late-stage trial
• Positive Sentiment: Analyst Cantor Fitzgerald raised its price target to $170 from $125 and maintained an overweight rating, reflecting increased confidence in bitopertin’s commercial and regulatory prospects. Disc Medicine delivers promise in successful pivotal study
• Positive Sentiment: The APOLLO win has renewed investor focus on what some commentary describes as a valuation discount, suggesting potential upside if investors begin pricing in a successful FDA resubmission and future commercial revenue. Disc Medicine APOLLO win puts valuation discount in focus
• Neutral Sentiment: Disc Medicine announced a proposed $350 million underwritten offering of common stock and pre-funded warrants. The proceeds could strengthen its balance sheet and support regulatory, manufacturing, and commercial preparations, although the final terms were not provided. Disc Medicine announces proposed $350 million public offering
• Negative Sentiment: The planned equity financing could dilute existing shareholders and may limit further gains in the near term, particularly after the stock’s large rally. Unusually heavy put-option activity also indicates elevated hedging or bearish speculation. Disc Medicine launches $350 million public stock offering

Disc Medicine Company Profile

Disc Medicine, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving the production of red blood cells, iron metabolism and heme biology, areas that can contribute to anemia and other blood-related complications.

Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule therapy designed to modulate glycine transporter 1 and influence heme production. The company is evaluating bitopertin in conditions including erythropoietic protoporphyria, a rare disorder associated with painful light sensitivity, as well as polycythemia vera and other hematologic diseases.

The company is also developing additional therapies intended to regulate iron availability and address anemia associated with chronic or hematologic conditions.